About Bluejay Therapeutics
Bluejay Therapeutics is a company based in San Francisco (United States) founded in 2019 by Keting Chu was acquired by Mirum Pharmaceuticals in December 2025.. Bluejay Therapeutics has raised $243 million across 3 funding rounds from investors including T. Rowe Price, RA Capital and Mirum Pharmaceuticals. The company has 3 employees as of December 31, 2021. Bluejay Therapeutics offers products and services including Brelovitug and MASH Therapy. Bluejay Therapeutics operates in a competitive market with competitors including Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Presidio Pharmaceuticals, among others.
- Headquarter San Francisco, United States
- Employees 3 as on 31 Dec, 2021
- Founders Keting Chu
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$243 M (USD)
in 3 rounds
-
Latest Funding Round
$182 M (USD), Series C
May 01, 2024
-
Investors
T. Rowe Price
& 13 more
-
Employee Count
3
as on Dec 31, 2021
-
Acquired by
Mirum Pharmaceuticals
(Dec 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bluejay Therapeutics
Bluejay Therapeutics offers a comprehensive portfolio of products and services, including Brelovitug and MASH Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for chronic hepatitis D through clinical trials.
Preclinical treatment for metabolic dysfunction-associated steatohepatitis.
Unlock access to complete
Unlock access to complete
Funding Insights of Bluejay Therapeutics
Bluejay Therapeutics has successfully raised a total of $243M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $182 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $182.0M
-
First Round
First Round
(01 Jun 2020)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series C - Bluejay Therapeutics | Valuation | Frazier Life Sciences | |
| Aug, 2022 | Amount | Series B - Bluejay Therapeutics | Valuation | Arkin Holdings | |
| Jun, 2020 | Amount | Series A - Bluejay Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Bluejay Therapeutics
Bluejay Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, RA Capital and Mirum Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Bluejay Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Bluejay Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bluejay Therapeutics Comparisons
Competitors of Bluejay Therapeutics
Bluejay Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Presidio Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Developer of therapies to treat hepatologic diseases and viral infections
|
|
| domain | founded_year | HQ Location |
Therapies for chronic hepatitis B and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule antiviral therapeutics for hepatitis C are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bluejay Therapeutics
Frequently Asked Questions about Bluejay Therapeutics
When was Bluejay Therapeutics founded?
Bluejay Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Bluejay Therapeutics located?
Bluejay Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Bluejay Therapeutics?
Keting Chu is the current CEO of Bluejay Therapeutics. They have also founded this company.
Is Bluejay Therapeutics a funded company?
Bluejay Therapeutics is a funded company, having raised a total of $243M across 3 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Jun 01, 2020.
How many employees does Bluejay Therapeutics have?
As of Dec 31, 2021, the latest employee count at Bluejay Therapeutics is 3.
What does Bluejay Therapeutics do?
Therapeutics targeting infectious diseases, particularly hepatitis B virus, are developed by Bluejay Therapeutics. The company was founded in 2019 and is headquartered in San Francisco, United States. Lead candidates include BJT-778, a monoclonal antibody aimed at restoring adaptive immunity, and BJT-754, an oral small molecule inhibitor for HBV infection. Operations focus on advancing these assets through clinical development in the biotechnology sector.
Who are the top competitors of Bluejay Therapeutics?
Bluejay Therapeutics's top competitors include Eiger BioPharmaceuticals, AusperBio and Finch Therapeutics.
What products or services does Bluejay Therapeutics offer?
Bluejay Therapeutics offers Brelovitug and MASH Therapy.
Who are Bluejay Therapeutics's investors?
Bluejay Therapeutics has 14 investors. Key investors include T. Rowe Price, RA Capital, Mirum Pharmaceuticals, HBM Healthcare Investments, and Arkin Holdings.